Stockscreener 앱 받기
400.52
5.27%
20.05
시간 외 거래:
407.00
6.48
+1.62%
전일 마감가:
$380.47
열려 있는:
$375.61
하루 거래량:
924.67K
Relative Volume:
1.33
시가총액:
$18.07B
수익:
$2.99B
순이익/손실:
$1.21B
주가수익비율:
15.98
EPS:
25.06
순현금흐름:
$1.13B
1주 성능:
+31.42%
1개월 성능:
+31.40%
6개월 성능:
+28.79%
1년 성능:
+14.43%
1일 변동 폭
$375.61
$401.62
1주일 범위
$375.61
$436.95
52주 변동 폭
$266.98
$436.95
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
400.52 | 17.21B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
153.32 | 67.90B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.40 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.80 | 44.04B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.20B | 16.70B | -157.13M | 1.19B | -0.155 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Is United Therapeutics Corporation a turnaround storyLong Setup & Precise Buy Zone Identification - خودرو بانک
What’s the RSI of United Therapeutics Corporation stockIPO Watch & Proven Capital Preservation Methods - خودرو بانک
United Therapeutics EVP Mahon sells $4.2m in shares - Investing.com
United Therapeutics EVP Mahon sells $4.2m in shares By Investing.com - Investing.com UK
Oppenheimer Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
Published on: 2025-09-05 01:07:29 - خودرو بانک
Using Bollinger Bands to evaluate United Therapeutics CorporationMarket Performance Summary & Long-Term Capital Growth Strategies - Newser
UTHR: HC Wainwright & Co. Raises Price Target for United Therape - GuruFocus
Is United Therapeutics Corporation meeting your algorithmic filter criteria2025 Market Overview & Fast Moving Trade Plans - Newser
United Therapeutics stock price target raised to $500 from $400 at H.C. Wainwright - Investing.com
United Therapeutics Corporation’s volatility index tracking explainedJuly 2025 Setups & Entry Point Confirmation Signals - Newser
United Therapeutics stock price target raised to $560 from $415 at UBS - Investing.com Canada
Will United Therapeutics Corporation benefit from rate cutsQuarterly Market Summary & Reliable Price Breakout Alerts - خودرو بانک
Does United Therapeutics Corporation have declining or rising EPSJuly 2025 Closing Moves & Weekly Market Pulse Updates - khodrobank.com
What’s next for United Therapeutics Corporation stock price2025 Growth vs Value & Daily Momentum Trading Reports - Newser
How hedge fund analytics apply to United Therapeutics Corporation stock2025 Bull vs Bear & Verified Entry Point Detection - Newser
United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement - simplywall.st
Detecting support and resistance levels for United Therapeutics Corporation2025 Technical Overview & Accurate Intraday Trade Tips - Newser
Mannkind Corporation shares rise 1.22% premarket after United Therapeutics' drug Tyvaso shows significant lung function improvement. - AInvest
Is United Therapeutics Corporation forming a bottoming baseJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Does United Therapeutics Corporation show high probability of rebound2025 Big Picture & High Conviction Buy Zone Picks - Newser
Is United Therapeutics Corporation stock entering bullish territoryDividend Hike & Daily Entry Point Trade Alerts - Newser
Can machine learning forecast United Therapeutics Corporation recovery2025 Valuation Update & Long Hold Capital Preservation Tips - Newser
How to build a dashboard for United Therapeutics Corporation stockWall Street Watch & Daily Stock Trend Watchlist - Newser
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results - Stocktwits
United Therapeutics: On the Rise? - timothysykes.com
Why United Just Catapulted 39%, Pulling Two Rivals With It - Investor's Business Daily
United Therapeutics Shares Soar: Will Momentum Last? - StocksToTrade
Moving Averages: Is United Therapeutics Corporation stock influenced by commodity prices2025 Pullback Review & High Accuracy Swing Trade Signals - khodrobank.com
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results - citybiz
United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest? - CryptoRank
United Therapeutics stock jumps as Jefferies raises price target on IPF study - Investing.com
United Therapeutics stock hits all-time high on successful drug trial - The Business Journals
UBS Lifts United Therapeutics’ Price Target to Drive Optimism - StocksToTrade
UBS Lifts United Therapeutics Price Target Amid Positive Study Results - timothysykes.com
United’s Tyvaso surprise in IPF potentially opens $4B market - BioWorld MedTech
Why Is United Therapeutics Stock Rallying On Tuesday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics stock hits all-time high at $419.63 - Investing.com
United Therapeutics shares surge as lung disease drug meets main study goal - TradingView
PepsiCo, United Therapeutics Lead Market Cap Stock Movers on Tuesday - Investing.com
United Therapeutics shares surge after Tyvaso IPF trial hits key goal - MSN
United Therapeutics’ Stunning Leap: What’s Behind It? - StocksToTrade
United Therapeutics' TETON-2 Trial Shows Tyvaso Improves Lung Function In IPF Patients - Nasdaq
PepsiCo, Ionis Pharma, United Therapeutics - TradingView
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis - MarketScreener
United Therapeutics posts Tyvaso trial win (UTHR:NASDAQ) - Seeking Alpha
United Therapeutics Announces Positive TETON-2 Study Results - TipRanks
95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial - Stock Titan
Published on: 2025-09-01 20:26:35 - Newser
Published on: 2025-09-01 19:48:53 - Newser
What is United Therapeutics Corporation’s valuation compared to sectorPortfolio Return Report & Weekly Market Pulse Alerts - khodrobank.com
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.54%
자본화:
|
볼륨(24시간):